Stifel Nicolaus Initiates Tokai Pharmaceuticals With Buy

by Monica Gerson, Benzinga Staff Writer
October 13, 2014 7:30 AM | 12 seconds read |
Analysts at Stifel Nicolaus initiated coverage on Tokai Pharmaceuticals TKAI with a Buy rating. The target price for Tokai Pharmaceuticals is set to $20. Tokai Pharmaceuticals' shares rose 2.34% to close at $11.82 on Friday.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: InitiationAnalyst RatingsStifel Nicolaus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!